← Leaderboard
RB
Robert Blum
Cytokinetics (President and CEO)
First call on the ledger
No calls filed yet. Quotes in curly quotation marks are verbatim; everything
else is a labeled paraphrase. Every call links its original source. Before you trust the call, check the record.
Where they stand
Views on the record but not scoreable bets: no single number and deadline to grade. Shown in their exact words, never scored.
Asked what concerns him about building biotech companies today, he says companies like his 'would be far more difficult to build today, in part because we don't have an industrial policy, a nationwide commitment to science' @36:40, that the erosion is 'more acute care now over the last two to three years' @37:05 (garbled, likely 'acute here'), and that the slide runs from 'commoditization of pharmaceutical ingredients' to supply chains, clinical trials and 'ultimately to medicines for patients' @38:26.
“I would say that there's a natural competitive advantage that is beginning to be ceded to China for the fact that they've made a deliberate strategic commitment to a policy industrialization”
Follow Robert Blum
One short email when Robert puts a new call on the record, and when a verdict lands on one. Plain words, free.